NCT00654992

Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery

Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.

Detailed description

Acute kidney injury (AKI) occurs in 7% to 40% of patients undergoing cardiac surgery, depending on the definition of AKI used. Even small increments in serum creatinine have been shown to be associated with increased mortality after cardiac surgery. However, there are no proven interventions to prevent AKI after cardiac surgery. Erythropoietin (EPO) has been shown to have tissue-protective effects in various experimental models. In this prospective placebo-controlled randomized trial, we evaluated the effectiveness of EPO in the prevention of AKI after coronary artery bypass grafting (CABG).

Conditions

• Kidney Failure, Acute

Interventions

Type	Name	Description
DRUG	Erythropoietin-Beta	300 IU/kg of EPO or saline intravenously before surgery
DRUG	Normal Saline	300 IU/kg of normal saline intravenously before surgery

Timeline

• Start date: 2006-09-01
• Primary completion: 2008-02-01
• Completion: 2009-02-01
• First posted: 2008-04-09
• Last updated: 2009-06-16
• Results posted: 2009-06-16

Locations

1 site across 1 country: South Korea